Expression and diagnostic values of MIAT, H19, and NRON long non-coding RNAs in multiple sclerosis patients

Abstract

Background Multiple sclerosis (MS) is a chronic inflammatory disease. Various long non-coding RNAs (lncRNAs) appear to have an important role in the pathophysiology of MS. This study aimed at evaluating the expression levels of lncRNAs, MIAT, H19, and NRON in peripheral blood of MS cases to a healthy control group. We collected blood samples of 95 MS cases (76 relapsing–remitting (RR) and 19 secondary progressive (SP) MS) and 95 controls. We used quantitative real-time PCR for the evaluation of gene expression. The correlation between expression with clinical parameters was analyzed by a multiple linear regression model. Receiver operating characteristic (ROC) curve analysis was carried out to detect the diagnostic potential of lncRNAs levels according to the area under the curve (AUC). Results MIAT, H19, and NRON were significantly increased in the RRMS and SPMS subgroups compared to the controls. We found that the H19 and MIAT expression significantly were higher in SPMS compared with RRMS. Patients with RRMS had a greater level of the average NRON expression is compared with SPMS patients. The expression level of H19 significantly was higher in females relative to male patients. Based on the area under curve (AUC) values, NRON had the best performance in the differentiation of MS patients from controls (AUC = 0.95, P < 0.0001). A combination of MIAT, H19, and NRON expression levels could be useful in differentiating MS patients with 93.6% sensitivity, 98.9% specificity, and diagnostic power of 0.96 (P < 0.0001). Conclusions The levels of MIAT, H19, and NRON in peripheral blood could be important biomarkers for MS diagnosis.

Expression analysis of vitamin D receptor-associated long noncoding RNAs in patients with relapsing-remitting multiple sclerosis

“…However, some studies suggest that lncRNA H19 is implicated in CNS diseases through the JAK/STAT pathway and the activation and proliferation of astrocytes and microglia (30). Consistent with our fi ndings, Amiri et al found that the expression of lncRNA H19 is signifi cantly higher in SPMS and RRMS subgroups compared to healthy individuals (31). However, in the study by Meber et al, it was reported that the serum levels of lncRNA H19 in MS patients were lower than in healthy subjects (27).…”

Diagnostic potential of LncRNAs-ANRIL and MIAT in the blood of patients with cerebral venous thrombosis

“…Previous results con rmed the in ammatory effect of MIAT up-regulation with a positive correlation with disease severity in IS [38,39], coronary artery disease [40], multiple sclerosis [41], and cancer [42]. The in ammatory mechanisms of MIAT has been suggested to participate in endothelial in ammation, vascular dysfunction [43], vascular leakage and upregulation of IL-1β and IL-6 [44].…”

Diagnostic efficacy of long non-coding RNAs in multiple sclerosis: a systematic review and meta-analysis

“…Subsequent careful screening of abstracts led to the exclusion of 295 articles. Final inclusion criteria—excluding animal cell experiments, non-blood sample studies, data extraction issues, reviews, and comments—resulted in 13 studies ( Gharesouran et al, 2019b ; Sayad et al, 2019 ; Shaker et al, 2019 ; Ghaiad et al, 2020 ; Senousy et al, 2020 ; Safa et al, 2021 ; Soltanmoradi et al, 2021 ; Akbari et al, 2022 ; Amiri et al, 2022 ; Attia et al, 2023 ; Ghafouri-Fard et al, 2023 ; Kamal et al, 2023 ; Kortam et al, 2023 ) qualifying for the meta-analysis. This process is detailed in Figure 1 .…”